title: Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
abstract: The aim of this article is to focus on the fixed-dose combination of phentermine and topiramate, a new antiobesity drug recently approved by the US FDA. The mechanisms of weight loss for each drug in monotherapy is described, followed by the rationale for its use as a combination therapy and a comprehensive review of recently published clinical trials that assessed its efficacy  and safety.
authors: Obesity & Metabolic Syndrome Unit, Division of Endocrinology & Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil. brunohalpern@hotmail.com
authors: Bruno
authors: B
authors: Halpern
authors: André M
authors: AM
authors: Faria
authors: Alfredo
authors: A
authors: Halpern
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D010645:Phentermine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D004338:Drug Combinations; D000077236:Topiramate; D005632:Fructose; D010645:Phentermine